Michael Davis, PhD

Michael Davis, PhD has a diverse work experience in the scientific field. Michael currently serves as a Senior Scientist at Interline Therapeutics, a position they have held since September 2022. Prior to this, they worked as a Scientist II at Applied Molecular Transport until September 2022.

Before joining the industry, Michael gained extensive research experience. Michael was a Research Fellow (Project Leader and Scientist) at The National Institutes of Health from 2014 to 2022. Their work there focused on investigating host-directed immune therapy drug mechanisms of action against pulmonary infectious diseases. Michael made notable contributions by studying the drug's effects on adaptive, myeloid, and structural cells as well as cytokine networks. Michael also discovered novel interactions of inflammatory pathways with implications for pulmonary diseases.

During their time at the University of Michigan Medical School from 2011 to 2014, Michael served as a Pulmonary Research Fellow (Post Doc Scientist and Project Leader). Michael led projects on macrophage polarization plasticity and the host-microbe interaction of macrophage and Cryptococcus during infection with Cryptococcus neoformans. Their research on macrophage polarization plasticity gained significant recognition and is one of the most cited papers in mBio journal history. Additionally, they invented a flow cytometry assay to measure lysosome damage in mouse lung phagocytes, a breakthrough method that was previously only applicable to tissue culture.

Before starting their research career, Michael worked as an intern at Bend Research Inc in 2009.

Overall, Michael Davis, PhD has a strong background in scientific research, with expertise in pulmonary diseases, macrophage biology, and drug mechanisms of action.

Michael Davis, PhD, completed their education from the University of Michigan Medical School and Michigan State University. Michael earned their Bachelor of Science (BS) degree in Microbiology from Michigan State University in the years 1999 to 2003. Later, they pursued further studies at the University of Michigan Medical School, specializing in Immunology, and obtained their PhD in this field from 2004 to 2011.